Chronic selective endothelin a receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease

Hypertension

Volumn 58, Issue 2, 2011, Pages

  Dhaun, Neeraj ^a,b   Johnston, Neil R ^a   Goddard, Jane ^b   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ATRASENTAN; BOSENTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; NIFEDIPINE; PLACEBO; PROTEIN; SITAXSENTAN; URIC ACID;

ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; DISEASE COURSE; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY BLOOD FLOW; KIDNEY TUBULE ABSORPTION; LETTER; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PULMONARY HYPERTENSION; PULSE WAVE; RENAL PROTECTION; URIC ACID BLOOD LEVEL;

CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HYPERTENSION; HYPERURICEMIA; ISOXAZOLES; KIDNEY FAILURE, CHRONIC; RECEPTOR, ENDOTHELIN A; THIOPHENES; TREATMENT OUTCOME; URIC ACID;

EID: 80051475258     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.175646     Document Type: Letter

References (12)

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821.
2. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404-2410. (Pubitemid 30257539)
3. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-1551. (Pubitemid 38970476)
4. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642-650. (Pubitemid 39237608)
5. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59. (Pubitemid 41828266)
6. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-440. (Pubitemid 47481999)
7. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-932.
8. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17: 943-955.
9. Dhaun N, Macintyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772-779.
10. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39: 1227-1233. (Pubitemid 350193621)
11. Raichlin E, Prasad A, Mathew V, Kent B, Holmes DR Jr, Pumper GM, Nelson RE, Lerman LO, Lerman A. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension. 2008;52:522-528.
12. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M. Bosentan therapy for chronic thromboembolic pulmonary hypertension: a national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly. 2007;137: 573-580.